Evidence map›Paper›PMID 39399826›Full record

ArticleInternational journal of nanomedicine2024

Nanocarrier-Assisted Delivery of Berberine Promotes Diabetic Alveolar Bone Regeneration by Scavenging ROS and Improving Mitochondrial Dysfunction.

Ye Ming, Xinyi He, Zhenxing Zhao, Xuehuan Meng, Ye Zhu, Hao Tan, Guoyin Yang, Yun Hu, Leilei Zheng

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Au-PtNPs@MnACS omega · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Nanomedicines Against Mitochondrial Dysfunction-Induced Metabolic Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  11. Article
  12. Article
  13. Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025
    Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ye Ming *College of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Xinyi He *College of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Zhenxing Zhao *College of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Xuehuan MengCollege of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Ye ZhuCollege of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Hao TanCollege of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Guoyin YangCollege of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Yun HuCollege of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.
Leilei ZhengCollege of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Oxidative stress and mitochondrial dysfunction are potential contributors to the compromised tissue regeneration capacity of alveolar bone in diabetic patients. Berberine, an active plant alkaloid, exhibits multiple pharmacological effects including antioxidation, blood glucose- and blood lipid-lowering properties. However, it remains uncertain whether berberine can improve impaired osteogenesis in type 2 diabetes mellitus (T2DM), and its poor solubility and oral bioavailability also constrain its applications in bone regeneration. Thus, our study aimed to probe the effects of berberine on bone marrow stem cells (BMSCs) in a diabetic microenvironment, with a greater emphasis on developing a suitable nano-delivery system for berberine and assessing its capability to repair diabetic alveolar bone defects. Methods: Firstly, BMSCs were exposed to berberine within a high glucose and palmitate (HG+PA) environment. Reactive oxygen species levels, mitochondrial membrane potential, ATP generation, cell apoptosis, and osteogenic potential were subsequently assessed. Next, we explored the regulatory mechanism of autophagy flux in the positive effects of berberine. Furthermore, a nanocarrier based on emulsion electrospinning for sustained local delivery of berberine (Ber@SF/PCL) was established. We assessed its capacity to enhance bone healing in the alveolar bone defect of T2DM rats through micro-computed tomography and histology analysis. Results: Berberine treatment could inhibit reactive oxygen species overproduction, mitochondrial dysfunction, apoptosis, and improve osteogenesis differentiation by restoring autophagy flux under HG+PA conditions. Notably, Ber@SF/PCL electrospun nanofibrous membrane with excellent physicochemical properties and good biological safety had the potential to promote alveolar bone remodeling in T2DM rats. Conclusion: Our study shed new lights into the protective role of berberine on BMSCs under T2DM microenvironment. Furthermore, berberine-loaded composite electrospun membrane may serve as a promising approach for regenerating alveolar bone in diabetic patients.

Indexed as

BerberineBone RegenerationDiabetes Mellitus, ExperimentalMesenchymal Stem CellsMitochondriaReactive Oxygen SpeciesAlveolar Bone LossAnimalsApoptosisCells, CulturedDiabetes Mellitus, Type 2Drug CarriersMaleMembrane Potential, MitochondrialOsteogenesisOxidative StressBerberineDrug CarriersPalmitatesReactive Oxygen Speciesalveolar bone remodelingautophagy fluxberberinediabetes mellituselectrospun nanofibrous membrane

Identifiers

PMID39399826
PMCPMC11471107

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.